News

Retina UK-funded discovery leads to $2.5 award for further research

A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards …

Your donations make progress possible

Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments. Here are just …

Light sensing small molecule given green light for clinical testing in Australia

Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). …

Meira GTx announces positive top-line data from phase 1/2 clinical trial of X-linked RP (RPGR) gene therapy

Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by …

Cane tip with improved sensory and auditory function launched

If you are a cane user, you may be interested to hear about the new cane tip introduced by Rotacaster that offers improved sensory and auditory feedback, alongside many other …

Sirius clinical trial – Exon 13 mutation of USH2A

Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets …

Retina UK awards new research funding

Retina UK is delighted to have awarded a new three-year research grant to Prof Majlinda Lako at Newcastle University for a project entitled: To establish AAV.PRPF31 gene augmentation in PRPF31-deficient …

A blog from the research coal face

Jing Yu is a bioinformatician with the Eye Research Group at Oxford University, and is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team, funded by a Retina UK  …

Our commitment to lived experience leadership and employment

In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our …

Research update – ProQR

In February this year, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10). These results prompted ProQR to undertake a …

Drugs for cancer and alcoholism show promise for RP

With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise. Investigating the potential of …

Notice of the forthcoming Retina UK AGM – July 2022

This year the AGM will be held on Saturday, 9 July at 4.00pm: Online, postal and telephone voting will be held in advance of the AGM meaning all members who …